| DIRECT COMPETITOR COMPARISON | |
| NWBO.OB | AGEN | Pvt1 | DNDN | Industry | | Market Cap: | 43.54M | 63.27M | N/A | 3.07B | 98.96M | | Employees: | 4 | 80 | N/A | 198 | 65 | | Qtrly Rev Growth (yoy): | 0.00% | 31.00% | N/A | -3.80% | 19.10% | | Revenue (ttm): | 10.00K | 3.31M | 1.30M1 | 108.00K | 13.84M | | Gross Margin (ttm): | 100.00% | 100.00% | N/A | 100.00% | 65.67% | | EBITDA (ttm): | -16.53M | -24.94M | N/A | -74.09M | -12.25M | | Oper Margins (ttm): | -165,480.00% | -881.51% | N/A | -72,917.59% | -149.46% | | Net Income (ttm): | -26.15M | -26.79M | -23.00M1 | -196.49M | N/A | | EPS (ttm): | -0.594 | -0.366 | N/A | -1.915 | -0.31 | | P/E (ttm): | N/A | N/A | N/A | N/A | 17.51 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.28 | | P/S (ttm): | 4644.64 | 18.98 | N/A | 27932.23 | 10.12 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.42 | 0.12% | 58.12B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.24 | 0.15% | 15.11B | 17.48 | | Genzyme Corp. | GENZ | 48.50 | 0.62% | 12.87B | 27.65 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.00 | -0.02% | 38.70B | 16.63 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.17 | 0.68% | 9.30B | 1064.69 | | Teva Pharmaceutical Industries Limited | TEVA | 55.94 | -0.07% | 49.28B | 51.18 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.91 | 0.28% | 4.24B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.14 | -0.82% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.74 | 0.00% | 5.73B | 114.97 | | Pfizer Inc. | PFE | 18.60 | 0.11% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.70 | 0.20% | 178.51B | 14.13 | | GlaxoSmithKline plc | GSK | 42.29 | 0.48% | 107.21B | 13.87 | | Sanofi-Aventis | SNY | 39.87 | 0.43% | 104.11B | N/A | | Novartis AG | NVS | 54.84 | 0.44% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.20 | 0.93% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 0.89% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.15 | 0.11% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.76 | 0.23% | 51.03B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AGEN | | Mentor Capital Cancer Vaccine Investing Update
Wed 12:53pm -
at Seeking Alpha | | • | DNDN | | Ten Predictions for 2010
Tue, Dec 22 -
at The Wall Street Journal Online | | • | DNDN | | 3 Reasons to Sell Dendreon Today
Fri, Dec 18 -
at Motley Fool | | • | DNDN | | 3 Reasons to Buy Dendreon Today
Fri, Dec 18 -
at Motley Fool | | • | AGEN | | Biotech Stock Mailbag: Year in Review
Fri, Dec 18 -
at TheStreet.com | | • | DNDN | | Five Biotech Events to Watch in 2010
Wed, Dec 16 -
at TheStreet.com | | • | DNDN | | Five Biotech Events to Watch in 2010
Wed, Dec 16 -
TheStreet.com | | • | DNDN | | What Will Be the Best Stock for 2010?
Tue, Dec 15 -
at Motley Fool | | • | AGEN | | Still Believe in Antigenics
Tue, Nov 24 -
at Seeking Alpha | | • | AGEN | | Antigenics pulls European Oncophage application
Fri, Nov 20 -
AP | | • | AGEN | | ANTIGENICS INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Fri, Nov 20 -
EDGAR Online | | • | AGEN | | European CHMP Formally Adopts Negative Opinion on Oncophage®
Fri, Nov 20 -
Business Wire | | • | AGEN | | ANTIGENICS INC /DE/ Financials
Fri, Nov 13 -
EDGAR Online Financials | | | All Headlines for these symbols... |
|
|
|
0.51% Nasdaq 
0.05 (6.25%) 
Competitors
